The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.

Leukemia & lymphoma

Volumn 51, Issue 3, 2010, Pages 376-389

  Alousi, Amin M ^a   Uberti, Joseph ^b   Ratanatharathorn, Voravit ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ALLOTRANSPLANTATION; B LYMPHOCYTE; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; PATHOPHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77957751168     PISSN: None     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903586318     Document Type: Review

References (0)